RNTX
Rein Therapeutics Inc. NASDAQ Listed Jun 29, 2017$0.99
+9.81%
vs $0.90
Mkt Cap $27.7M
52w Low $0.86
9.8% of range
52w High $2.18
50d MA $1.21
200d MA $1.28
P/E (TTM)
—
EV/EBITDA
—
P/B
1.5x
Debt/Equity
0.0x
ROE
-294.8%
P/FCF
-1.2x
RSI (14)
26.90
ATR (14)
$0.08
Beta
1.40
50d MA
$1.21
200d MA
$1.28
Avg Volume
651.2K
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
12407 N. Mopac Expy. · Austin, TX 78758 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -1.09 | -1.09 | +0.0% | 1.27 | -2.4% | -1.6% | +1.6% | +2.4% | -6.9% | +0.0% | — |
| Nov 14, 2025 | AMC | -0.24 | -0.21 | +12.5% | 1.25 | -2.4% | -2.4% | +0.0% | +3.3% | +9.5% | +7.2% | — |
| Aug 14, 2025 | AMC | -0.22 | -0.28 | -27.3% | 1.16 | -1.7% | +2.6% | -5.0% | -2.7% | +4.5% | -1.7% | — |
| Apr 7, 2025 | AMC | -0.14 | -0.26 | -85.7% | 1.64 | +4.9% | -15.2% | +4.3% | +7.6% | +9.6% | -2.9% | — |
| Dec 31, 2024 | AMC | -0.46 | -1.89 | -310.7% | 2.30 | +0.0% | -2.2% | +1.3% | -8.3% | -1.9% | -5.9% | — |
| Nov 14, 2024 | AMC | -0.25 | -0.27 | -8.0% | — | — | — | — | — | — | — | — |
| Aug 14, 2024 | AMC | -0.25 | -0.45 | -80.0% | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | AMC | -0.14 | -0.86 | -512.0% | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | -0.16 | -1.54 | -840.0% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -0.20 | -0.40 | -101.2% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | -0.40 | -0.39 | +1.6% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 21 | Brookline Capital | Downgrade | Buy → Hold | — | $1.20 | $1.18 | -1.7% | +0.8% | +10.7% | +2.2% | +13.1% | +0.0% |
| Aug 19 | Brookline Capital | Downgrade | Buy → Hold | — | $1.13 | $1.20 | +6.2% | -2.7% | +4.5% | -1.7% | +12.4% | -7.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 27, 2026 | VON RICKENBACH JOSEF H | — | Buy | 4,500 | $1.07 | $5K | 62,514 | +0.00% | +0.00% |
| May 26, 2026 | VON RICKENBACH JOSEF H | — | Buy | 23,190 | $1.06 | $24K | 58,014 | +0.00% | +0.00% |
| May 22, 2026 | VON RICKENBACH JOSEF H | — | Buy | 15,950 | $1.05 | $17K | 34,824 | +0.00% | +0.00% |
| May 21, 2026 | VON RICKENBACH JOSEF H | — | Buy | 3,420 | $1.04 | $4K | 18,874 | +0.00% | +0.00% |
| Apr 30, 2026 | WINDSOR JAMES BRIAN | See Remarks | Buy | 25,000 | $1.00 | $25K | 27,046 | -2.59% | -2.55% |
8-K
Rein Therapeutics Inc. -- 8-K Filing
Rein Therapeutics executed an underwriting agreement for a securities offering, establishing mutual obligations, indemnification provisions, and standard closing conditions between the company and underwriters.
May 4
8-K · 1.01
! Medium
Rein Therapeutics, Inc. -- 8-K 1.01: Financing / Debt Agreement
Rein Therapeutics secured convertible notes maturing upon a $10 million equity raise or June 2026, whichever occurs first, providing runway while incentivizing future capital raises.
Mar 2
8-K
Rein Therapeutics, Inc. -- 8-K Filing
I cannot provide a meaningful analysis from this filing summary, as it contains only administrative incorporation details without substantive business information or deal announcements relevant to investors.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Voss Capital, Lp | 4,388,362 | $6M | Added | Mar 2026 |
| 2 | Bios Capital Management, Lp | 1,690,751 | $2M | — | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 998,521 | $1M | New | Mar 2026 |
| 4 | Sigma Planning Corp | 247,277 | $299K | Reduced | Dec 2025 |
| 5 | Northern Trust Corp | 64,136 | $83K | Added | Mar 2026 |
| 6 | Jane Street Group, Llc | 61,960 | $72K | New | Dec 2025 |
| 7 | Northwestern Mutual Wealth Management Co | 42,440 | $49K | — | Dec 2025 |
| 8 | Exencial Wealth Advisors, Llc | 30,528 | $40K | New | Mar 2026 |
| 9 | Meridian Wealth Advisors, Llc | 28,486 | $37K | — | Mar 2026 |
| 10 | Renaissance Technologies Llc | 24,500 | $32K | Added | Mar 2026 |
| 11 | Sanders Morris Harris Llc | 20,000 | $26K | New | Mar 2026 |
| 12 | Cane Capital Partners, Llc | 18,000 | $23K | — | Mar 2026 |
| 13 | Kg&l Capital Management,llc | 18,000 | $21K | — | Dec 2025 |
| 14 | Hrt Financial Lp | 15,486 | $20K | Reduced | Mar 2026 |
| 15 | Steelpeak Wealth, Llc | 13,000 | $17K | New | Mar 2026 |
| 16 | Hightower Advisors, Llc | 10,000 | $12K | New | Dec 2025 |
| 17 | Rockefeller Capital Management L.p. | 5,097 | $7K | — | Mar 2026 |
| 18 | Us Bancorp \de\ | 1,250 | $1K | — | Dec 2025 |
| 19 | Ubs Group Ag | 1,024 | $1K | Reduced | Mar 2026 |
| 20 | Wells Fargo & Company/mn | 20 | $26 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 113,421 | $129K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 64,973 | $84K | Mar 2026 |
| 3 | Fidelity Nasdaq Composite Index ETF | 67,187 | $77K | Feb 2026 |
| 4 | Fidelity Total Market Index Fund | 35,242 | $40K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 27,869 | $32K | Feb 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 8,122 | $9K | Feb 2026 |
Valuation
Market Cap
$27.7M
Enterprise Value
$19.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
1.49x
P/S
—
P/FCF
-1.19x
EV/EBITDA
—
Shares Out
25.4M
Financials (TTM)
Revenue
$0
Net Income
-$50.2M
EBITDA
-$21.5M
Free Cash Flow
-$19.4M
Op Cash Flow
-$19.4M
EPS Basic
$-1.96
EPS Diluted
$-1.90
EPS Forward
$-1.63
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$24.2M
Total Liab.
$7.2M
Total Equity
$16.9M
Cash
$3.2M
LT Debt
$0
Book Value/Sh
$0.66
Debt/Equity
0.00x
Current Ratio
0.70
Quick Ratio
0.70
Returns & Growth
ROE
-294.8%
ROA
-206.4%
ROIC
-120.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+44.2%
Price Returns
2W
-1.8%
1M
-18.4%
3M
-2.6%
6M
-29.3%
12M
-43.1%
Technicals
52W High
$2.18
52W Low
$0.86
50d MA
$1.21
200d MA
$1.28
RSI (14)
26.90
ATR (14)
$0.08
Beta
1.40
Avg Volume
651K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 26, 2026 11:16pm
· Source: financialmodelingprep.com